Additional treatment with BRI significantly reduced GRP78 mRNA expression, and cotreatment with LAT or OMD significantly downregulated the mRNA expressions of CHOP, GRP78, and sXBP-1 compared to the tunicamycin-treated group. The gene discussed is DDIT3; the disease is occult macular dystrophy.